T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Oportun Financial
OPRT
$351M
| $127K | ﹤0.01% |
23,955
| – | – |
|
2902
Universal Electronics
UEIC
$71M
| $126K | ﹤0.01% |
34,686
| – | – |
|
2903
ChargePoint
CHPT
$162M
| $125K | ﹤0.01% |
+18,778
| New | +$177K |
|
2904
AerSale
ASLE
$271M
| $124K | ﹤0.01% |
17,368
| – | – |
|
|
SEVN
2905
Seven Hills Realty Trust
SEVN
$175M
| $123K | ﹤0.01% |
+13,772
| New | +$129K |
|
2906
Spire Global
SPIR
$539M
| $122K | ﹤0.01% |
16,223
+2,471
| +18% | +$24.2K |
|
2907
VTEX
VTEX
$630M
| $122K | ﹤0.01% |
32,306
+3,389
| +12% | +$13.9K |
|
2908
KULR Technology Group
KULR
$138M
| $121K | ﹤0.01% |
40,578
+4,757
| +13% | +$17.5K |
|
2909
CS Disco
LAW
$285M
| $121K | ﹤0.01% |
15,571
| – | – |
|
2910
AEye
LIDR
$60.9M
| $119K | ﹤0.01% |
64,380
| – | – |
|
2911
Liberty Latin America Class A
LILA
$1.67B
| $118K | ﹤0.01% |
23,328
| – | – |
|
2912
Tredegar Corp
TG
$276M
| $118K | ﹤0.01% |
16,305
+2,707
| +20% | +$20.5K |
|
|
AVR
2913
Anteris Technologies
AVR
$866M
| $115K | ﹤0.01% |
22,875
+10,073
| +79% | +$46.2K |
|
2914
Agilon Health
AGL
$1.47B
| $114K | ﹤0.01% |
6,678
-1,664
| -20% | -$32.3K |
|
2915
LifeVantage
LFVN
$81.5M
| $113K | ﹤0.01% |
18,234
+4,600
| +34% | +$34.1K |
|
2916
Radiant Logistics
RLGT
$407M
| $113K | ﹤0.01% |
17,780
| – | – |
|
2917
Atomera
ATOM
$215M
| $111K | ﹤0.01% |
50,139
| – | – |
|
2918
Larimar Therapeutics
LRMR
$445M
| $111K | ﹤0.01% |
29,008
+6,038
| +26% | +$23.5K |
|
2919
Protara Therapeutics
TARA
$232M
| $111K | ﹤0.01% |
20,736
+4,383
| +27% | +$24.4K |
|
2920
Palladyne AI
PDYN
$311M
| $111K | ﹤0.01% |
25,910
+13,100
| +102% | +$88.2K |
|
2921
loanDepot
LDI
$304M
| $109K | ﹤0.01% |
52,286
+11,003
| +27% | +$30.6K |
|
2922
Outset Medical
OM
$85.7M
| $107K | ﹤0.01% |
28,627
+13,800
| +93% | +$118K |
|
2923
Quantum-Si Incorporated
QSI
$191M
| $107K | ﹤0.01% |
96,486
+4,452
| +5% | +$7.25K |
|
2924
Rezolute
RZLT
$454M
| $107K | ﹤0.01% |
45,088
+3,630
| +9% | +$28.5K |
|
2925
Senseonics Holdings Inc
SENS
$415M
| $105K | ﹤0.01% |
+18,900
| New | +$132K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.